Alnylam announced the resignation of its CFO, Manmeet Soni, and revealed his replacement with Jeff Poulton, the former CFO of rare disease-focused biotech Shire, which Takeda acquired last year for $62bn (€55.28bn).
The RNAi drugmaker stated that Soni has decided to resign to ‘pursue other interests’, and John Maraganore, the company’s CEO, commented on his contributions to Alnylam’s development, “where he led the buildout of our global financial and operational infrastructure and strengthened the company’s balance sheet with over $1.5bn in new equity capital.”
Maraganore added that Poulton, the incoming CFO, “brings a wealth of experience” to Alnylam that is ‘ideal’ for the company’s looks.
Prior to his fifteen-year tenure at Shire, Poulton held financial leadership positions at Cinergy Corp and PPG industries, while he is currently also a member of the board of directors of EIP Pharmaceuticals.
In a statement, Poulton commented on the ‘unmatched’ opportunity to join Alnylam’s leadership in their goals, including the commercial launch of Onpattro (patisiran), an approved treatment for polyneuropathy, the regulatory authorisation of a second investigational RNAi therapeutic and the advancement of several products in Phase III.